文献速递心外重症与机械循环支持

阿哌沙班作为HeartMate 3左心室辅助装置患者治疗性抗凝的经验

Apixaban as therapeutic anticoagulation in patients supported by a fully magnetically levitated left ventricular assist device.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-08-27

单中心回顾性研究评估阿哌沙班作为HeartMate 3左心室辅助装置患者主要长期抗凝药的安全性和有效性。113例患者平均年龄57岁,随访272.8患者年,出血事件发生率0.158次/患者年,严重出血0.062次/患者年,缺血性卒中0.022次/患者年,无泵血栓和溶血事件,1年和5年生存率分别为86%和51%。

要点

  • 阿哌沙班用于HeartMate 3患者主要长期抗凝,出血事件0.158次/患者年,严重出血0.062次/患者年。
  • 缺血性卒中发生率为0.022次/患者年,无泵血栓和溶血事件发生。
  • 1年和5年生存率分别为86%和51%。

核心结论

  • 阿哌沙班是HeartMate 3左心室辅助装置患者安全有效的首选和长期治疗性抗凝药。

研究设计与样本

  • 单中心回顾性综述,纳入2018年1月至2025年10月期间以阿哌沙班作为主要和长期抗凝治疗的HeartMate 3左心室辅助装置患者。
  • 使用Interagency Registry for Mechanically Assisted Circulatory Support数据库评估患者临床数据和不良事件。
  • 共纳入113例患者,平均年龄57岁,男性占70%,白人占71%;41%为缺血性心肌病,25%为特发性心肌病,21%为其他心肌病。
  • INTERMACS分级:12%为1级,35%为2级,43%为3级,10%为4级。

主要发现

  • 阿哌沙班治疗总随访272.8患者年,平均2.4年。
  • 23例患者(20%)发生出血事件,出血事件发生率为0.158次/患者年,严重出血事件发生率为0.062次/患者年。
  • 12例患者发生12次卒中(10%),缺血性卒中事件发生率为0.022次/患者年。
  • 无泵血栓和溶血事件发生。
  • 1年和5年生存率分别为86%和51%。

临床怎么用

  • 对于HeartMate 3左心室辅助装置患者,可考虑使用阿哌沙班作为主要和长期治疗性抗凝药。
  • 使用阿哌沙班抗凝时需关注出血和卒中风险,本研究显示出血和缺血性卒中发生率较低,无泵血栓和溶血事件。

局限性

  • 本研究为单中心回顾性研究,结果需在其他中心人群中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The HeartMate 3 left ventricular assist device is an established therapy for patients with advanced heart failure. Warfarin has been the recommended anticoagulant for patients supported by the HeartMate 3 left ventricular assist device; however, it is accompanied by complications secondary to the lack of time in therapeutic range, dosage-related issues, and medical burden. In this study, we present our experience with apixaban as an alternative primary and chronic anticoagulant for patients supported with the HeartMate 3 left ventricular assist device. METHODS: We performed a single-center retrospective review of patients who were supported with the HeartMate 3 left ventricular assist device from January 2018 to October 2025 who were treated with apixaban as the primary and chronic anticoagulant. The Interagency Registry for Mechanically Assisted Circulatory Support database was used to evaluate patient clinical data and adverse events. Patients were assessed for survival and adverse events, including bleeding, stroke, pump thrombosis, and hemolysis. RESULTS: A total of 113 patients supported with the HeartMate 3 left ventricular assist device were treated with apixaban as the primary and chronic anticoagulant. Patients had a mean age of 57 years and were predominantly male (70%) and White (71%); 41% were diagnosed with ischemic cardiomyopathy, 25% with idiopathic cardiomyopathy, and 21% with other cardiomyopathies. By Interagency Registry for Mechanically Assisted Circulatory Support profile, patients were classified as 12% profile 1, 35% profile 2, 43% profile 3, and 10% profile 4. There was a total of 272.8 patient-years on apixaban with a mean of 2.4 years. A total of 23 patients (20%) experienced a bleeding event. There were 0.158 bleeding events per patient-year with only 0.062 severe bleeding events per patient-year. Twelve patients had 12 strokes (10%) with 0.022 ischemic stroke events per patient-year. There was no pump thrombosis or hemolysis events. Survival at 1 year and 5 years was 86% and 51%, respectively. CONCLUSIONS: Apixaban is a safe and effective primary and chronic therapeutic anticoagulant for patients on a HeartMate 3 left ventricular assist device.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Crane JG, Samson R, Moore S, et al. Apixaban as therapeutic anticoagulation in patients supported by a fully magnetically levitated left ventricular assist device. J Thorac Cardiovasc Surg. 2026. PMID: 42660443. doi:10.1016/j.jtcvs.2026.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。